Physician profile
Dennis Chan
NPI 1053343434
$5,277.49
in general payments reported to CMS, 2019-2025
17 companies · $720 in 2025
The $720 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $448 · 2021: $454 · 2022: $1,139 · 2023: $451 · 2024: $847 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,593.53 | 2019-2024 | Skyrizi, Rinvoq |
| Gilead Sciences, INC. | $1,461.84 | 2019-2024 | Vemlidy, Livdelzi |
| Madrigal Pharmaceuticals | $399.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $299.96 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $217.76 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Braintree Laboratories, INC. | $196.04 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $161.36 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $156.73 | 2020-2022 | |
| Apollo Endosurgery US INC | $139.18 | 2023 | Overstitch Endoscopic Suturing System |
| Allergan, INC. | $126.58 | 2019 | |
| Pfizer INC. | $125.00 | 2025 | |
| Novo Nordisk INC | $124.95 | 2025 | Wegovy |
| Dova Pharmaceuticals | $69.95 | 2019 | |
| Ferring Pharmaceuticals INC. | $61.07 | 2020-2021 | |
| Janssen Biotech, INC. | $56.11 | 2025 | Tremfya, Stelara, Simponi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $37.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.